Another benefit to methylation profiling is that it can inclusively recognize oncogenic variants of IDH1/2 and can be further subclassed into tumor types based on epigenetic marks (for example, astrocytoma or oligodendroglioma) [170,175]. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).